Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Coleman RE, et al. Among authors: hadji p. Clin Cancer Res. 2008 Oct 15;14(20):6387-95. doi: 10.1158/1078-0432.CCR-08-1572. Clin Cancer Res. 2008. PMID: 18927277 Free PMC article. Review.
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV; EUROFORS Investigators. Boonen S, et al. Among authors: hadji p. J Clin Endocrinol Metab. 2008 Mar;93(3):852-60. doi: 10.1210/jc.2007-0711. Epub 2007 Dec 26. J Clin Endocrinol Metab. 2008. PMID: 18160462 Clinical Trial.
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T; EUROFORS Investigators. Obermayer-Pietsch BM, et al. Among authors: hadji p. J Bone Miner Res. 2008 Oct;23(10):1591-600. doi: 10.1359/jbmr.080506. J Bone Miner Res. 2008. PMID: 18505369 Free article. Clinical Trial.
Metastasis and bone loss: advancing treatment and prevention.
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Coleman RE, et al. Among authors: hadji p. Cancer Treat Rev. 2010 Dec;36(8):615-20. doi: 10.1016/j.ctrv.2010.04.003. Epub 2010 May 15. Cancer Treat Rev. 2010. PMID: 20478658 Free PMC article. Review.
Consensus on the utility of bone markers in the malignant bone disease setting.
Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, Dimopoulos M, Lipton A. Coleman R, et al. Among authors: hadji p. Crit Rev Oncol Hematol. 2011 Dec;80(3):411-32. doi: 10.1016/j.critrevonc.2011.02.005. Epub 2011 Mar 15. Crit Rev Oncol Hematol. 2011. PMID: 21411334 Review.
Treatment of bone metastases before the onset of pain.
Costa L, Lipton A, Hadji P, Chen YM, Kosmidis P. Costa L, et al. Among authors: hadji p. Int J Clin Oncol. 2013 Jun;18(3):531-8. doi: 10.1007/s10147-012-0414-8. Epub 2012 May 11. Int J Clin Oncol. 2013. PMID: 22572805 Clinical Trial.
Denosumab and fracture risk in women with breast cancer.
Coleman R, Hadji P. Coleman R, et al. Among authors: hadji p. Lancet. 2015 Aug 1;386(9992):409-10. doi: 10.1016/S0140-6736(15)61032-7. Epub 2015 May 31. Lancet. 2015. PMID: 26040500 No abstract available.
294 results